Re-registration of Deanxit (Flupentixol and Melitracen) has been approved by the China Food and Drug Administration (“CFDA”) that Deanxit gained a new Imported Drug License with the term of 5 years.
The successful renewal of Imported Drug License of Deanxit provides the drug with legal protection and legal support to achieve sustainable sales growth of the drug in the China market.